Lenzetto (Estradiol)

Estradiol released from the patch enters the bloodstream and binds to estrogen receptors ERα and ERβ in target cells. This binding triggers gene transcription that restores estrogenic activity in tissues such as bone, the central nervous system, and the urogenital tract, alleviating menopausal symptoms and supporting bone health.

The prescribed dose of Lenzetto is determined by the treating physician based on the individual’s clinical condition, severity of symptoms, and response to therapy. The prescriber selects the appropriate patch strength and replacement interval; patients should follow the specific instructions provided by their healthcare professional.

Estradiol is contraindicated in pregnancy because it may affect fetal development. Limited data are available for breastfeeding; however, estrogen can pass into breast milk and may suppress lactation. Women who are pregnant, planning pregnancy, or nursing should discuss alternative therapies with their clinician.

To order Lenzetto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenzetto delivers estradiol transdermally, bypassing first‑pass metabolism and providing more stable plasma levels than oral estradiol tablets. Compared with other patches such as Vivelle‑Dot, Lenzetto offers similar efficacy but may differ in patch size, adhesion properties, and dosing schedule, which the prescriber will consider when selecting therapy.

Lenzetto patches should be stored at room temperature, below 25 °C, in their original sealed packaging. Protect them from moisture, direct sunlight, and extreme temperatures. Do not expose the patch to heat sources or store in a refrigerator, as this could affect adhesion and drug release.

Lenzetto is applied to clean, dry, hair‑free skin on the lower abdomen or upper buttock. The patch is worn for the prescribed period (usually one week) and then replaced with a new patch at a different site to avoid skin irritation. Patients should follow the application instructions provided with the product.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, and stroke. Additional concerns are myocardial infarction, hepatic dysfunction, and estrogen‑dependent malignancies. Patients should be monitored for signs of these conditions and advised to seek immediate medical attention if symptoms arise.

Lenzetto is contraindicated in women with known or suspected estrogen‑dependent cancers (e.g., breast or endometrial cancer), active thromboembolic disease, unexplained vaginal bleeding, severe liver disease, or those who are pregnant. Caution is also advised for patients with a history of cardiovascular disease or uncontrolled hypertension.